Anteris Technologies (AVR) Surges 11.39% on $90M Medtronic Investment, Trial Progress

The share price of Anteris Technologies (AVR) surged to its highest level so far this month, with an intraday gain of 11.39% on 23 January. The stock has climbed 46.33% over six consecutive trading days, marking a sharp reversal in momentum for the medical technology firm. The rally follows a $90 million strategic investment from Medtronic and a $230 million public offering, alongside progress in its pivotal PARADIGM trial for the DurAVR Transcatheter Heart Valve (THV).

Anteris secured $320 million in funding through a combination of a 40 million-share public offering and a private placement with Medtronic, which acquired 15.65 million shares at $5.75 each. The partnership with Medtronic, a global leader in medical devices, underscores validation of Anteris’ biomimetic THV technology. The proceeds will advance the PARADIGM trial, a randomized study evaluating the DurAVR THV’s efficacy against existing TAVR solutions. Medtronic’s endorsement and the capital infusion have alleviated liquidity concerns, with the company’s CEO describing the move as a “major milestone” for innovation in structural heart disease.

Investor optimism is driven by the alignment of clinical progress, strategic collaboration, and financial stability. The DurAVR THV’s ADAPT tissue technology, already used in over 55,000 patients, positions Anteris to compete in the $5 billion TAVR market. Medtronic’s ownership stake (16–19.99% post-offering) signals long-term strategic alignment, potentially accelerating commercialization. While regulatory risks and competition remain, the capital raise and trial advancements have reshaped investor sentiment, with the stock’s 6-day gain reflecting confidence in Anteris’ ability to scale its technology and expand into new therapeutic areas.